Skip to main content
. 2023 Jun 2;14:1078992. doi: 10.3389/fpsyg.2023.1078992

Table 1.

Characteristics of patients enrolled in the SarCorD study and included/excluded from QoL analysis.

Patients included in the analysis Patients excluded from the analysis
N = 114 N = 258
N (%) N (%)
Age (mean ± SD) 54.3 ± 16.57 58.4 ± 18.5
Gender
M 66 (57.9) 162 (62.8)
F 48 (42.1) 96 (37.2)
Educational level
Until first level of secondary school 34 (29.8) 32 (12.4)
Equal or upper than second level of secondary school 75 (65.8) 55 (21.3)
Unknown 5 (4.4) 171 (66.3)
Occupational status
No 50 (43.9) 35 (13.6)
Yes 58 (50.9) 50 (19.4)
Unknown 6 (5.2) 173 (67.0)
Civil status
Single/divorced/widowed 42 (36.8) 15 (5.8)
Married/cohabiting 62 (54.4) 58 (22.5)
Unknown 10 (8.8) 185 (71.7)
Sons
No 23 (20.2) 34 (13.2)
Yes 62 (54.4) 77 (29.8)
Unknown 29 (25.4) 147 (57.0)
Extension of the disease
Localized 97 (85.1) 198 (76.7)
Metastatic 15 (13.2) 32 (12.4)
Unknown 2 (1.7) 28 (10.9)
Hystotype
Soft tissue sarcoma/Dermatofibrosarcoma protuberans 72 (63.2) 164 (63.6)
Bone sarcoma/Ewing Sarcoma 33 (28.9) 50 (19.4)
Giant cell tumor of bone/Benign muscoloscheletal aggressive disease 8 (7.0) 21 (8.1)
Gastrointestinal stromal tumor/Kaposi sarcoma 1 (0.9) 23 (8.9)